September 2009 Br J Cardiol 2009;16:241
Peadar McKeown, Kerri Toland, Ian B A Menown
Figure 1. Electrocardiogram (ECG) showing new-onset atrial fibrillation Figure 3. Cardiac magnetic resonance image (MRI) consistent with a lymphoma tumour Figure 2. Echocardiography showing large intra-atrial mass One year previously he had been treated with six cycles of chemotherapy for aplastic large cell lymphoma. He had a pyrexia (38.5oC), elevated C-reactive protein (14.6 mg/L) and low haemoglobin (10.8 g/dL). As part of a screen for infection, echocardiography was performed to exclude endocarditis (figure 2), but revealed a large intra-atrial mass. Cardiac magnetic resonance imaging (MRI) (figure 3) appearance was consistent with a lym
September 2009 Br J Cardiol 2009;16:246
Rohit Tandon, Naveen Kumar, Naved Aslam, Naresh K Sood, Sanjeev Mahajan, Gurpreet S Wander, Bishav Mohan
Discussion Figure 1. Trans-oesophageal echocardiograph showing a large multi-lobed echogenic mass attached to interatrial septum and protruding into all four cardiac chambers via patent foramen ovale The transit of a thrombus across a patent foramen ovale has been serendipitously documented on imaging studies in extremely rare instances.1-4 Nearly 40 cases of thrombus in transit diagnosed ante mortem using various imaging studies have been described in the literature and only one case documenting the serial passage of a thrombus across a patent foramen ovale in real time.1,3 Figure 2. Trans-oesophageal echocardiograph image showing the long v
January 2008 Br J Cardiol 2008;15:35-9
Kiran CR Patel, Jennifer Prince, Seema Mirza, Lucy Edmonds, Rachel Duncan, Joanna Parry, Sally Jerome, John Wozniak, Nic Anfilogoff, Michael Frenneaux, Michael K Davies
Introduction Heart failure (HF) is common and is associated with a high morbidity and mortality. Forty per cent of patients with symptomatic left ventricular systolic dysfunction (LVSD) die within a year of diagnosis and 10% per annum thereafter, giving a five-year mortality rate of up to 70%.1 Estimates of the prevalence of symptomatic HF in the general European population range from 0.4–2%,2-4 with half of these patients suffering from LVSD and half from left ventricular diastolic dysfunction (LVDD).3,5 HF consumes nearly 2% of National Health Service (NHS) resources (a figure which will inevitably increase with the advent of relatively e
March 2007 Br J Cardiol 2007;14:83-89
Susan Wright
No content available
March 2007 Br J Cardiol 2007;14:99-101
John Chambers, Kevin Fox, Roxy Senior, Petros Nihoyannopoulos
No content available
March 2005 Br J Cardiol (Acute Interv Cardiol) 2005;12:AIC 5–AIC 7
Nick Curzen
No content available
September 2004 Br J Cardiol 2004;11:405-7
Ed Southall
No content available
September 2004 Br J Cardiol 2004;11:399-02
BJCardio editorial team
No content available
January 2004 Br J Cardiol 2004;11:75-9
Huw Williams, Elizabeth Morrison, Debra Elliott
No content available
May 2003 Br J Cardiol 2003;10:235-40
Han B Xiao
No content available
For healthcare professionals only
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits
